Literature DB >> 6708933

Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.

J W Lown, C C Hanstock, R D Bradley, D G Scraba.   

Abstract

The interactions of the low cardiotoxic antitumor agents 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione (mitoxantrone) and 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazoyl-2-yl)hydrazone] (bisantrene) with pBR322 and PM2 DNA have been examined by electron microscopy. Direct evidence was obtained for intercalative binding of both drugs, with mitoxantrone causing a 13% average length increase in pBR322 corresponding to approximately 580 drug molecules per circle at saturation and bisantrene causing an 11% increase in length corresponding to approximately 480 drug molecules bound per circle. Considerations of the known GC preference for non-nearest neighbor binding of the drugs and inspection of the known sequence of pBR322 suggest that the available intercalation sites are occupied and that additional external electrostatic binding of the cationic drugs also occurs. An apparent difference in behavior of mitoxantrone as compared with that of bisantrene in causing no net increase in length of supercoiled pBR322 was shown to be attributable to an offsetting compaction due to extensive supercoiling by mitoxantrone molecules. This conclusion was confirmed by independent experiments with PM2 covalently closed-circular DNA--both native, negatively supercoiled and relaxed--with calf thymus topoisomerase, using ethidium for comparison. Ethidium caused a 21.3 +/- 3.6% length increase in nicked, open-circular PM2-DNA, or 2100 molecules bound per 10,300 base pairs. Mitoxantrone caused a 16.6% length increase in nicked PM2-DNA equivalent to approximately 1700 drug molecules per circle. Electron microscopic measurements on relaxed PM2-DNA with progressively increasing proportions of mitoxantrone (from 1.4:1 to 14:1 drug molecules per base pair) revealed the onset of formation of lacelike networks of DNA circles linked together. This phenomenon, which is not produced by bisantrene, is attributed to inter-DNA links by the charged side arms of mitoxantrone and is in accord with previous reports that mitoxantrone causes severe compaction and distortion of chromatin. Electron microscopic examination of the interaction of six additional mitoxantrone derivatives, two of which produced lacelike DNA networks, revealed strict structural requirements for this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708933

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.

Authors:  L Capolongo; G Belvedere; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

3.  DNA sequence specificity of mitoxantrone.

Authors:  C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

4.  Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.

Authors:  Mandeep Atwal; Rebecca L Swan; Chloe Rowe; Ka C Lee; David C Lee; Lyle Armstrong; Ian G Cowell; Caroline A Austin
Journal:  Mol Pharmacol       Date:  2019-08-09       Impact factor: 4.436

5.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Development of mitoxantrone.

Authors:  R J White; F E Durr
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.

Authors:  V Heinemann; D Murray; R Walters; R E Meyn; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Authors:  R T Dorr; D S Alberts; M Soble
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.